Evidence map›Paper›PMID 20458745›Full record

ArticleJournal of cellular physiology2010

Functional mimicry of the acetylated C-terminal tail of p53 by a SUMO-1 acetylated domain, SAD.

Amrita Cheema, Chad D Knights, Mahadev Rao, Jason Catania, Ricardo Perez, Brigitte Simons, Sivanesan Dakshanamurthy, Vamsi K Kolukula, Maddalena Tilli, Priscilla A Furth and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of cellular physiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. PML, SUMOylation, and Senescence.Frontiers in oncology · 2013
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Amrita CheemaDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.
Chad D Knights
Mahadev Rao
Jason Catania
Ricardo Perez
Brigitte Simons
Sivanesan Dakshanamurthy
Vamsi K Kolukula
Maddalena Tilli
Priscilla A Furth
Christopher Albanese
Maria Laura Avantaggiati
Georgetown University Medical Center · USGeorgetown University · US

Funding

TRAINING GRANT IN TUMOR BIOLOGYT32CA009686 · NCI · GEORGETOWN UNIVERSITY · PI ANNA Tate RIEGEL, DAVID J ROBBINS · 1996 to 2026
$10.8M
MECHANISMS REGULATING REVERSAL OF PREMALIGNANCYR01CA089041 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI FURTH, PRISCILLA A. · 2001 to 2009
$2.0M
anti-tumor activity of deactylase inhibitorsR01CA102746 · NCI · GEORGETOWN UNIVERSITY · PI AVANTAGGIATI, MARIA L · 2004 to 2008
$1.4M
ACETYLTRANSFERASES AND ONCOGENESISR01CA083979 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AVANTAGGIATI, MARIA L · 1999 to 2003
$839k
Functional Mimicry of the p53 C-terminal Tail by the Ubiquitin-like Molecule SUMOR21CA123234 · NCI · GEORGETOWN UNIVERSITY · PI AVANTAGGIATI, MARIA L · 2008 to 2009
$380k
NCI NIH HHS R01 CA083979NCI NIH HHS R01 CA089041NCI NIH HHS R01 CA102746NCI NIH HHS R21 CA123234NCI NIH HHS R21CA123234NCI NIH HHS T32 CA009686
6 · The paper itself

Abstract

The ubiquitin-like molecule, SUMO-1, a small protein essential for a variety of biological processes, is covalently conjugated to many intracellular proteins, especially to regulatory components of the transcriptional machinery, such as histones and transcription factors. Sumoylation provides either a stimulatory or an inhibitory signal for proliferation and for transcription, but the molecular mechanisms by which SUMO-1 achieves such versatility of effects are incompletely defined. The tumor suppressor and transcription regulator p53 is a relevant SUMO-1 target. Particularly, the C-terminal tail of p53 undergoes both sumoylation and acetylation. While the effects of sumoylation are still controversial, acetylation modifies p53 interaction with chromatin embedded promoters, and enforces p53 apoptotic activity. In this study, we show that the N-terminal region of SUMO-1 might functionally mimic this activity of the p53 C-terminal tail. We found that this SUMO-1 domain possesses similarity with the C-terminal acetylable p53 tail as well as with acetylable domains of other transcription factors. SUMO-1 is, indeed, acetylated when conjugated to its substrates and to p53. In the acetylable form SUMO-1 tunes the p53 response by modifying p53 transcriptional program, by promoting binding onto selected promoters and by favoring apoptosis. By contrast, when non-acetylable, SUMO-1 enforces cell-cycle arrest and p53 binding to a different sets of genes. These data demonstrate for the first time that SUMO-1, a post-translational modification is, in turn, modified by acetylation. Further, they imply that the pleiotropy of effects by which SUMO-1 influences various cellular outcomes and the activity of p53 depends upon its acetylation state.

Indexed as

AcetylationAdenocarcinomaAmino Acid SequenceAnimalsApoptosisMiceMice, TransgenicProtein ConformationProtein Structure, TertiarySubmandibular Gland NeoplasmsSUMO-1 ProteinTranscription FactorsTumor Suppressor Protein p53SUMO-1 ProteinTranscription FactorsTumor Suppressor Protein p53

Identifiers

PMID20458745
PMCPMC3614007
OpenAlexW2130221956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.